



Codes ATC: L01FF02

Indication	Melanoma of skin <span style="background-color: #00a651; color: white; padding: 2px;">Code ICD11: 2C30</span>
INN	Pembrolizumab
Type de médicament	Biological agent
Type de liste	Liste de base
Additional notes	*including quality-assured biosimilars
Formulations	Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
Historique des statuts LME	Ajouté pour la première fois en 2025 (TRS 1064)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	nivolumab (Codes ATC: L01FF01) Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Renseignements sur le brevet	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Lire la suite <a href="#">sur les brevets.</a> 

## Balises

Cancer

## Wikipédia

[Pembrolizumab](#) 

## DrugBank

[Pembrolizumab](#) 

## Résumé des preuves et recommandation du comité d'experts

With the 2025 recommendation to list pembrolizumab for first-line monotherapy of metastatic non-small cell lung cancer with high PD-L1 expression ( $\geq 50\%$ ), first-line monotherapy for deficient mismatch repair/microsatellite instability-high metastatic colorectal cancer, and in combination with platinum-based chemotherapy, as first-line treatment of metastatic cervical cancer with PD-L1 expression  $\geq 1\%$ , the Expert Committee recommended changing the current square box listing of nivolumab as the class representative and pembrolizumab as the specified therapeutic alternative for metastatic melanoma, to make pembrolizumab the class representative with nivolumab as the specified therapeutic alternative. This is intended to signal to countries the possibility of aggregating procurement of a single molecule, pembrolizumab, for multiple cancer indications, which can influence price negotiations with manufacturers. Limiting procurement fragmentation by focusing on a select few immune checkpoint inhibitors is likely to facilitate central purchasing through competitive tendering and better competition from pembrolizumab biosimilars, thereby increasing access.

